Dr. Andrew Branagan, MD
Claim this profileMassachusetts General Hospital
Studies Plasma Cell Neoplasm
Studies Multiple Myeloma
10 reported clinical trials
22 drugs studied
Affiliated Hospitals
Clinical Trials Andrew Branagan, MD is currently running
Acalabrutinib + Rituximab
for Peripheral Neuropathy
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies. The names of the study drugs involved in this study are/is: * Acalabrutinib * Rituximab or similar CD20 antibody
Recruiting1 award Phase 28 criteria
CB-011
for Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Recruiting1 award Phase 14 criteria
More about Andrew Branagan, MD
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Andrew Branagan, MD has experience with
- Dexamethasone
- Rituximab
- Daratumumab
- Bortezomib
- Carfilzomib
- Pomalidomide
Breakdown of trials Andrew Branagan, MD has run
Plasma Cell Neoplasm
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Waldenstrom Macroglobulinemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Branagan, MD specialize in?
Andrew Branagan, MD focuses on Plasma Cell Neoplasm and Multiple Myeloma. In particular, much of their work with Plasma Cell Neoplasm has involved treating patients, or patients who are undergoing treatment.
Is Andrew Branagan, MD currently recruiting for clinical trials?
Yes, Andrew Branagan, MD is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Andrew Branagan, MD has studied deeply?
Yes, Andrew Branagan, MD has studied treatments such as Dexamethasone, Rituximab, Daratumumab.
What is the best way to schedule an appointment with Andrew Branagan, MD?
Apply for one of the trials that Andrew Branagan, MD is conducting.
What is the office address of Andrew Branagan, MD?
The office of Andrew Branagan, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02117 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.